Cervical Adenosquamous Cell Carcinoma Completed Phase 2 Trials for Pegfilgrastim (DB00019)

Also known as: Cervical Adenosquamous Carcinoma / Adenosquamous carcinoma of the cervix / Adenosquamous carcinoma of cervix (disorder)

IndicationStatusPhase
DBCOND0034091 (Cervical Adenosquamous Cell Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01266447Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical CancerTreatment